Eduardo Slatopolsky honored with 2007 ISN Amgen International Prize

April 24, 2007

Rio de Janeiro, Brazil, April 22, 2007 - The International Society of Nephrology (ISN) today announced Eduardo Slatopolsky, Joseph Friedman Professor of Renal Diseases in Medicine, Washington University School of Medicine (St. Louis, Missouri - USA) as the 2007 winner of the ISN Amgen International Prize for Therapeutic Advancement in Nephrology.

Established in 2003, the ISN Amgen International Prize recognizes those who have increased the understanding and treatment of kidney disease through basic or clinical scientific research, leading to therapeutic advances. This year's prize specifically recognizes Slatopolsky's pioneering experimental research in mineral metabolism which has undoubtedly improved the lives of patients with renal failure around the world.

With over 400 publications in basic and clinical sciences related to mineral metabolism - a testament to his outstanding contribution to the field, Slatopolsky has dedicated his entire career to the study of kidney disease with a 30 year record of major scientific achievements.

Receiving the prestigious prize during the 2007 Donald Seldin Plenary Lecture at the World Congress of Nephrology on April 22, Eduardo Slatopolsky expressed his thanks to ISN, Amgen and recognized the contribution of his laboratory members,

"I am deeply moved to be the recipient of this award of the ISN... it is a unique privilege that I have been selected for the ISN Amgen International Prize for Therapeutic Advancement in Nephrology. I accepted on behalf of my colleagues, with tremendous gratitude for having been selected as recipient."'

"Amgen congratulates Eduardo Slatopolsky on this important recognition by the ISN," said Robert Brenner, M.D. Executive Director Nephrology Medical Affairs. "Dr. Slatopolsky has made broad contributions to our understanding of the pathophysiology of secondary hyperparathyroidism, hyperphosphatemia and vitamin D biology. His efforts have driven treatment advances for patients with kidney disease around the world."
-end-
For media-related enquiries, please contact: Amanda Wren, International Society of Nephrology, Email: amanda.wren@isn-online.org, GSM: +32-473938672

EDITOR'S NOTES

1) The International Society of Nephrology is a not-for-profit society whose mission is the global advancement of nephrology. The Society promotes research and education to prevent and treat kidney disease throughout the world. Further information is available at: http://www.isn-online.org/, or by contacting the ISN's Global Headquarters: +32-2-743 1546, Email: info@isn-online.org.

2) Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

International Society of Nephrology

Related Kidney Disease Articles from Brightsurf:

Waistline matters in kidney disease
Does fat matter in kidney disease? The investigators found that all measures of higher abdominal fat content (including visceral fat, liver fat, or subcutaneous fat) and slower walk times were associated with increased levels of cardiometabolic risk factors in adults with non-dialysis dependent kidney disease.

Reducing urinary protein for patients with rare kidney disease slows kidney decline
New findings show that reducing the amount of protein in the urine of patients with focal segmental glomerulosclerosis can significantly slow declines in kidney function and extend time before patients' kidneys fail.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.

Genes tell a story about diabetic kidney disease
Studying Finnish genes leads to unique revelations about the development of a serious complication of diabetes, and informs an ongoing genomic study of a Singaporean cohort as part of Singapore's Diabetes Study in Nephropathy and other Microvascular Complications (DYNAMO).

New study provides insight into chronic kidney disease
Researchers have further analyzed a known signaling pathway they believe brings them one step closer to understanding the complex physiology of patients with chronic kidney disease (CKD), which might provide a path to new treatment options.

Predicting risk of chronic kidney disease
Data from about 5 million people (with and without diabetes) in 28 countries were used to develop equations to help identify people at increased five-year risk of chronic kidney disease, defined as reduced estimated glomerular filtration rate (eGFR).

A healthy diet may help prevent kidney disease
In an analysis of published studies, a healthy dietary pattern was associated with a 30% lower incidence of chronic kidney disease.

Is kidney failure a man's disease?
A new analysis of the ERA-EDTA Registry [1] reveals a striking gender difference in the incidence and prevalence of end-stage renal disease.

Chronic kidney disease: Everyone's concern
850 million people worldwide are affected by kidney disease. This worrying figure was published last June.

Read More: Kidney Disease News and Kidney Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.